KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer

doi:10.1002/mco2.545

MedComm ›› 2024, Vol. 5 ›› Issue (5) : e545. DOI: 10.1002/mco2.545

Yuwei Ding¹, Ying Yuan^1,^2,³(), Shanshan Weng¹()

Author information +

History +

Abstract

The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS≥1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.

Keywords

chemotherapy / gastric cancer / immunotherapy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Yuwei Ding, Ying Yuan, Shanshan Weng. KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer. MedComm, 2024, 5(5): e545 https://doi.org/10.1002/mco2.545

References

1	YY Janjigian, A Kawazoe, Y Bai, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet North Am Ed. 2023;402(10418):2197-2208.
2	YJ Bang, E Van Cutsem, A Feyereislova, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
3	K Yamaguchi, Y-J Bang, S Iwasa, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). J Clin Oncol. 2022;40(4):242-242.suppl.
4	K Shitara, SY Rha, LS Wyrwicz, et al. LBA74 pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: the phase III KEYNOTE-585 study. Ann Oncol. 2023;34:S1316.
5	N Li, Z Li, Q Fu, et al. Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2022;40(4):296-296. suppl.